## **Commercial Recruitment to Target**

	Research Ethics		Recruit			
1	Committee					Performance Against
10,911002/1   MCNR06s (1746-95)   1099   1	Reference			1		_
Intravenous caraminir versus oral oseitaminir in hospitalised influenza   2   27/02/2015   Open   Scrutiment   10/11/10/31/201   (Mark 14373 - 2060)   (		,				
19.0H1093/120   NA1141973 - 20R00   19.0H1093/120   19.0H109	10/H1002/1	, = ,	3	31/0//2013	witnarawn	
13,007,003,000,000,000,000,000,000,000,00	10/H1003/120	·	2	27/02/2015	Onen	•
NCRN322 TERRAIN: MDV3100 (ASP9785) vs. Bicalutamide Metastatic		,			•	
11/16/1262   CRN 592 (Uveitb)   10   30/05/2014   Up   Target Not Met   11/16/1263   CRN 592 (Uveitb)   10   30/05/2014   Up   Target Not Met   11/16/1263   CRN 592 (Uveitb)   10   30/05/2014   Up   Target Not Met   11/16/1263   CRN 592 (Uveitb)   10   31/10/2015   Withdrawn   Withdrawn   Withdrawn   Stationard Chemotherapy in Pediatric Palents with Newly   Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic   1   30/05/2014   Open   Recruitment   Added to Standard Chemotherapy in Pediatric Palents with Newly   Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic   1   30/05/2014   Open   Recruitment   Added to Standard Chemotherapy in Pediatric Palents with Newly   Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic   1   30/05/2014   Open   Recruitment   Newly   OCAVE A3921095: 007: Oral CP690,550 as an induction Therapy for   Uterative Collist   Stall Open to		, ,		. , . ,		
11/10/12/15   CRR 952 (Uverits)   10 30/06/2014   Up	11/LO/0608	Prostate Cancer	5	31/08/2013	Up	Target Met
11/10/1310   DEFLECT   Trial   G   31/13/2013   Closed - Fallow   Target Met   11/10/1329   Gallium   14   31/03/2015   Withdrawn   Withdrawn   Withdrawn   Withdrawn   11/10/1327   CRN 601 (Crohn's Disease)   5   30/06/2014   Open   Secrutiment   Study of Dasatinib   Added to Standard Chemotherapy in Pediatric Patients with Newly   Disgnosed Philadelphia Chromosome Positive Acade Lymphoblastic   13/08/2014   Open   Still Open to   Still Ope					Closed - In Follow	
11/10/1319   DEFLECT I Trial   14   31/03/2015   Withdrawn   Wit	11/LO/1226	CCRN 592 (Uveitis)	10	30/06/2014	•	Target Not Met
11/NV/0298   CRN 601 (Crohn's Disease)						
11/SC/0327   CRN 601 (Crohn's Disease)						
11/5C/0322	11/NW/0298	Gallium	14	31/03/2015	Withdrawn	
11/SC/0329   CCRN 602 (Crohn's disease)   5   31/10/2017   Open	11/50/0227	CCPN 601 (Crobn's Dispaso)	_	20/06/2014	Onon	•
11/5C/0329	11/3C/0327	CCKN 601 (CIOIIII'S DISEASE)	3	30/06/2014	Ореп	
A Phase Z MultiCenter, Historically Controlled Study of Dasastinib Added to Standard Chemotherapy in Pediatric Pathens with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL) 12/EM/0018 CCRN 738 (Post-Myocardial Infarction) OCTAVE A3921095: 007: Oral CP690,550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921095: 007: Oral CP690,550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921095: 007: Oral CP690,550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as Maintenance Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921096: 008: Oral CP6-90, 550 as an induction Therapy for Light Colorative Colitis OCTAVE A3921097: Global safety study with pertuzumab in Her2+ 3 30/04/2014 Open Still Open to Recruitment Still Open to Recruitment OCTAVE A3921097: Global safety study with pertuzumab Information Colorative A3921097: Open OCTAVE A3921097: Global safety study with pertuzumab Information Colorative Colitis OCTAVE A3921097: Global safety study with pertuzumab Information Colorative Colitis OCTAVE A3921139-009: Open-labe	11/SC/0329	CCRN 602 (Crohn's disease)	5	31/10/2017	Open	•
Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic   1 30/04/2014   Open	,,	,		. , ., .		
1,1/WA/0363   Leukemia (Ph+ ALL)   1 30/04/2014   Open   Recruitment   12/EM/0081   CCRN 738 (Post-Myocardial Infarction)   8 31/12/2013   Withdrawn   Withdrawn   OCTAVE A3921095: 007: Oral (P690,550 as an induction Therapy for   12/LO/0081   Ulcerative Colitis   Sill open to   Sill open		Added to Standard Chemotherapy in Pediatric Patients with Newly				
12/EM/0018   CCRN 738 (Post-Myocardial Infarction)		Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic				Still open to
OCTAVE A3921095: 007: Oral CP690,550 as an induction Therapy for Uzi/LO/0080 Ulcerative Colitis   Sill open to Recruitment   Si	11/WA/0363	, ,				Recruitment
	12/EM/0018		8	31/12/2013	Withdrawn	
OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for 12/LO/0082   Ulcerative Collits   Still open to Recruitment					_	•
	12/LO/0080		5	30/09/2014	Open	
PERUSE (MO28047): Global safety study with pertuzumab in Her2+ advanced BC   S 31/03/2016   Withdrawn   Withdrawn   Closed - In Follow   Target Met	12/10/0091		2	21/12/2014	Onon	•
12/LO/0482   advanced BC   5   31/03/2016   Withdrawn   Withdrawn   Withdrawn   12/SC/0025   BRIGHTER (CRFB002E2402)   5   31/05/2013   Up   Target Met   12/SC/0025   Target Met   Target Met   Target Met   Target Met   Target Mot Met   Target Met   Target Mot	12/10/0081		3	31/12/2014	Ореп	Recruitment
12/SC/0025   BRIGHTER (CRFB002E2402)   5   31/05/2013	12/10/0482	, , , , , , , , , , , , , , , , , , , ,	5	31/03/2016	Withdrawn	Withdrawn
12/SC/0025   BRIGHTER (CRFB002E2402)   5   31/05/2013   Up   Target Met   12/SW/0084   LFG316 MPC   5   28/02/2014   Suspended   Target Not Met   12/SW/0084   LFG316 MPC   5   28/02/2014   Suspended   Target Not Met   10/H0711/66   BLAST NCRN170   2   31/12/2013   Up   Target Met   10/H1308/84   NCRN252 - Nilotinib in paediatric Ph+ CML/ALL   1   31/05/2015   Open   Recruitment   Still open to   Recruitment   Recruitment   11/L0/0923   NCRN259 HERBY - Bevacizumab in paediatric high grade glioma   3   22/08/2017   Open   Recruitment   11/L0/1023   CCRN 492 (Branch retinal vein occlusion)   10   31/10/2013   Up   Target Met   Closed - In Follow   Target Met   Target Met   Closed - In Follow   Target Met   Target Met   Closed - In Follow   Target Met   Closed - In Follow   Target Met   Target Met   Closed - In Follow   Target Net   Closed - In Follow   Target Met   Closed - In Follow   Target Net   Closed - In Follow   Target Not Met   Closed - In Follow   Target Not Met   Closed - In Follow   Target Not Met   Closed - Follow   Target Not Met	12/20/0402	davanced be		31,03,2010		Withdrawii
10/H0711/66   BLAST NCRN170	12/SC/0025	BRIGHTER (CRFB002E2402)	5	31/05/2013	Up	Target Met
10/H0711/66   BLAST NCRN170   2   31/12/2013   Up   Target Met   Still open to   Still open	12/SW/0084	LFG316 MFC	5	28/02/2014	Suspended	Target Not Met
Still open to   Still open t					Closed - In Follow	
10/H1308/84   NCRN252 - Nilotinib in paediatric Ph+ CML/ALL   1   31/05/2015   Open   Recruitment   Still open to   Still open to   Recruitment   Still open to   Recruitment   Still open to   Still open to   Recruitment   Still open to   Still open to   Recruitment   Still	10/H0711/66	BLAST NCRN170	2	31/12/2013	Up	_
1/LO/0923   NCRN259 HERBY - Bevacizumab in paediatric high grade glioma   3   22/08/2017   Open   Recruitment						•
11/LO/0923   NCRN259   HERBY - Bevacizumab in paediatric high grade glioma   3   22/08/2017   Open   Recruitment	10/H1308/84	NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	1	31/05/2015	Open	
11/LO/1023   CCRN 492 (Branch retinal vein occlusion)   10   31/10/2013   Up   Target Met	11/10/0022	NCPN250 HEPPY Povacizumah in pandiatric high grade glioma	2	22/09/2017	Onon	·
11/LO/1023   CCRN 492 (Branch retinal vein occlusion)   10   31/10/2013   Up   Target Met	11/10/0923	NCKIV233 TEKBT - Bevacizumas in paediatric nign grade giloma	3	22/08/2017	•	Recruitment
11/SC/0177 CCRN 530 (Hep C)  1 31/08/2013 Up Target Met  11/VM/0279 NECTAR-HF Research Study  10/H0808/138 CCRN 499 (CV)  10/H0808/138 CCRN 499 (CV)  10/H0808/138 CCRN 499 (CV)  10/H0806/106 DLBCL  10/H0406/106 DLBCL  10/H0406/47 ABBOTT 327 CCRN 283 (LT uveitis)  10/H0406/45 ABBOTT 877 CCRN 281 (Active uveitis)  10/H0406/46 ABBOTT 880 CCRN 282 (Inactive uveitis)  11/SC/028 Ventilator.  12/SW/0228 Ventilator.  12/SW/0228 Trastuzumab Emtansine (TDM1) (GATSBY)  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  10/H04084 CRN 499 (CV)  10 28/02/2014 Up Target Not Met  10 28/02/2014 Up Complete  10 28/02/2014 Up Com	11/LO/1023	CCRN 492 (Branch retinal vein occlusion)	10	31/10/2013		Target Met
Closed - In Follow   Target Not Met						J
11/VM/0279 NECTAR-HF Research Study  10/H0808/138 CCRN 499 (CV)  10/H0808/138 CCRN 499 (CV)  10/H0808/138 CCRN 499 (CV)  10/H0808/138 CCRN 499 (CV)  10/H0806/106 DLBCL  10/H0406/106 DLBCL  10/H0406/47 ABBOTT 327 CCRN 283 (LT uveitis)  10/H0406/47 ABBOTT 327 CCRN 283 (LT uveitis)  10/H0406/45 ABBOTT 877 CCRN 281 (Active uveitis)  10/H0406/46 ABBOTT 880 CCRN 282 (Inactive uveitis)  10/H0406/46 ABBOTT 880 CCRN 283 (LT uveitis)  11/H0406/46 A	11/SC/0177	CCRN 530 (Hep C)	1	31/08/2013	Up	Target Met
10/H0808/138 CCRN 499 (CV) 10/H0808/138 CCRN 499 (CV) 10/H0808/138 CCRN 499 (CV) 10/H0806/106 DLBCL 10/H0406/106 DLBCL 10/H0406/47 ABBOTT 327 CCRN 283 (LT uveitis) 10/H0406/47 ABBOTT 877 CCRN 281 (Active uveitis) 10/H0406/45 ABBOTT 877 CCRN 281 (Active uveitis) 10/H0406/46 ABBOTT 877 CCRN 282 (Inactive uveitis) 10/H0406/46 ABBOTT 880 CCRN 282 (Inactive uveitis) 10/H0406/46 ABBOTT 877 CCRN 281 (Active uveitis)					Closed - In Follow	
10/H0808/138	11/VM/0279	NECTAR-HF Research Study	6	31/12/2013	•	Target Not Met
NCRN069 ORCHARRD - Ofatumumab vs Rituximab followed by ASCT in DIBCL Still open to Target Not Met Still open to Recruitment Still open to Recruitmen						
Description of the property of	10/H0808/138	, ,	10	28/02/2014	•	Target Not Met
Still open to Recruitment  ABBOTT 327 CCRN 283 (LT uveitis)  8 30/09/2014 Open Recruitment  Still open to Recruitment  Still open to Recruitment  10/H0406/45 ABBOTT 877 CCRN 281 (Active uveitis)  4 16/09/2014 Open Recruitment  Still open to Recruitment  10/H0406/46 ABBOTT 880 CCRN 282 (Inactive uveitis)  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  37 30/11/2013 Up Target Not Met  Closed - In Follow  Closed - In Follow  Target Not Met  Still open to Recruitment  Closed - In Follow  Target Not Met  Still open to  Still open to  Still open to  Still open to  Recruitment  Target Not Met  Still open to  Still open to  Recruitment  12/LO/0082 Ulcerative Colitis  5 31/12/2014 Open Recruitment  Still open to  Recruitment  Still open to  Recruitment  Still open to  Recruitment  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open Recruitment  Closed - In Follow	00/110406/106		_	21/10/2012		Target Net Met
ABBOTT 327 CCRN 283 (LT uveitis)  8 30/09/2014 Open Recruitment  Still open to Recruitment  10/H0406/45 ABBOTT 877 CCRN 281 (Active uveitis)  4 16/09/2014 Open Recruitment  Still open to Recruitment  10/H0406/46 ABBOTT 880 CCRN 282 (Inactive uveitis)  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  37 30/11/2013 Up Target Not Met  12/LO/1358 NCRN532 (TAS 102)  Target Not Met  12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of 12/LO/0082 Ulcerative Colitis  DCTAVE B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open Recruitment  Closed - In Follow  Still open to Still open to Recruitment	09/10406/106	DEBCE	3	31/10/2013	op complete	
Still open to Recruitment  ABBOTT 877 CCRN 281 (Active uveitis)  ABBOTT 880 CCRN 282 (Inactive uveitis)  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228  Ventilator.  37 30/11/2013 Up  Closed - In Follow  12/LO/1358  NCRN532 (TAS 102)  7 31/12/2013 Up  Target Not Met  Closed - In Follow  Still open to Recruitment  2 31/07/2014 Up  Target Not Met  Still open to Ulcerative Colitis  5 31/12/2014 Open  Recruitment  Still open to Recruitment  Still open to Recruitment  12/LO/0082  INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open  Recruitment  Closed - In Follow  Still open to Recruitment	10/H0406/47	ABBOTT 327 CCRN 283 (LT uveitis)	8	30/09/2014	Onen	•
ABBOTT 877 CCRN 281 (Active uveitis)  ABBOTT 877 CCRN 281 (Active uveitis)  ABBOTT 880 CCRN 282 (Inactive uveitis)  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  37 30/11/2013 Up Target Not Met  Closed - In Follow  12/LO/1358 NCRN532 (TAS 102)  7 31/12/2013 Up Target Not Met  Still open to  12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of  12/LO/0082 Ulcerative Colitis  5 31/12/2014 Open Recruitment  Still open to  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open Recruitment  Closed - In Follow  Still open to  Recruitment  1 28/10/2014 Open Recruitment  Closed - In Follow  Closed - In Follow  Still open to  Recruitment	20/110 100/17	7.655 17 527 GG.III 255 (27 disciss)		30,03,201	Орен	
ABBOTT 880 CCRN 282 (Inactive uveitis)  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  37 30/11/2013 Up Target Not Met Closed - In Follow  12/LO/1358 NCRN532 (TAS 102)  7 31/12/2013 Up Target Not Met  12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of 12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  A 17/08/2014 Open Recruitment  A 17/08/2014 Open Recruitment  Still open to 12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  A 17/08/2014 Open Recruitment  1 28/10/2014 Open Recruitment  Closed - In Follow	10/H0406/45	ABBOTT 877 CCRN 281 (Active uveitis)	4	16/09/2014	Open	·
A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  12/LO/1358 NCRN532 (TAS 102)  12/LO/1358 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis  12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  37 30/11/2013 Up Target Not Met  Closed - In Follow  Still open to Still open to Still open to Treatment of Ulcerative Colitis  5 31/12/2014 Open Recruitment  Closed - In Follow						Still open to
exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy  12/SW/0228 Ventilator.  12/LO/1358 NCRN532 (TAS 102)  12/LO/1358 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis  12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  Closed - In Follow  Target Not Met  Still open to  Recruitment  Still open to  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  Closed - In Follow  Closed - In Follow  13/12/2014 Open  Recruitment  Still open to  Recruitment  Closed - In Follow	10/H0406/46	· · · · · · · · · · · · · · · · · · ·	4	17/08/2014	Open	Recruitment
hospital and follow-up use at home: feasibility of using the Trilogy  Ventilator.  37 30/11/2013 Up  Target Not Met  Closed - In Follow  Closed - In Follow  Target Not Met  12/LO/1358 NCRN532 (TAS 102)  7 31/12/2013 Up  Target Not Met  Still open to  Recruitment  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of  12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open  Recruitment  Closed - In Follow  Closed - In Follow  Anglet Not Met  Still open to  Recruitment  Still open to  Recruitment  Closed - In Follow  Closed - In Follow						
12/SW/0228 Ventilator. 37 30/11/2013 Up Target Not Met  12/LO/1358 NCRN532 (TAS 102) 7 31/12/2013 Up Target Not Met  12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY) 2 31/07/2014 Open Recruitment  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of  12/LO/0082 Ulcerative Colitis 5 31/12/2014 Open Recruitment  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia 1 28/10/2014 Open Recruitment  Closed - In Follow						
12/LO/1358 NCRN532 (TAS 102)  7 31/12/2013 Up  Target Not Met  Still open to  Recruitment  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of  12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  Closed - In Follow  Still open to  31/12/2014 Open  Recruitment  Still open to  Recruitment  Still open to  Recruitment  Closed - In Follow	42/04/0220	, , , , , , , , , , , , , , , , , , , ,	27	20/11/2012		T+ NI-+ N 4-+
12/LO/1358 NCRN532 (TAS 102) 7 31/12/2013 Up Target Not Met 12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY) 2 31/07/2014 Open Recruitment OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of 12/LO/0082 Ulcerative Colitis 5 31/12/2014 Open Recruitment Still open to Recruitment Still open to 12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia 1 28/10/2014 Open Recruitment Closed - In Follow	12/500/0228	venulator.	37	30/11/2013	•	rarget NOT Met
Still open to 12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of 12/LO/0082 Ulcerative Colitis  INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  Indicate the still open to an incident of the still open to an incident	12/10/1358	NCRN532 (TAS 102)	7	31/12/2012		Target Not Met
12/NW/0585 Trastuzumab Emtansine (TDM1) (GATSBY)  OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis  12/LO/0082 Ulcerative Colitis  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia  1 28/10/2014 Open Recruitment Still open to Recruitment  Still open to Recruitment Closed - In Follow	12/10/1330	1100 100 100 100	,	31, 12, 2013		
OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis  5 31/12/2014 Open Recruitment Still open to Recruitment 12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia 1 28/10/2014 Open Recruitment Closed - In Follow	12/NW/0585	Trastuzumab Emtansine (TDM1) (GATSBY)	2	31/07/2014	Open	·
12/LO/0082 Ulcerative Colitis 5 31/12/2014 Open Recruitment  12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia 1 28/10/2014 Open Recruitment  1 Closed - In Follow	. ,		_	, . ,		
12/SC/0309 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia 1 28/10/2014 Open Recruitment Closed - In Follow	12/LO/0082	Ulcerative Colitis	5	31/12/2014	Open	-
Closed - In Follow						-
	12/SC/0309	INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia	1	28/10/2014		Recruitment
12/5C/U469  EFC12492: Udyssey FH I   5   08/04/2013   Up   Target Met	12/56/2452	FFC(12402) Oct 1999 FILE	_	00/04/2015		Township 6
	12/5C/0469	EFC12492: Udyssey FH I	5	08/04/2013	Up	i arget iviet

## **Commercial Recruitment to Target**

Docoarch Fibir-		Doort			
Research Ethics Committee		Recruit ment	Recruitment		Performance Against
Reference	Study Title		End Date	Study Status	Target
Reference	Study Title	laiget	Liiu Date	Closed - In Follow	laiget
12/SC/0540	BI 207127 in Treatment-Naïve Patients with HCV	5	30/06/2013		Target Not Met
12/30/0340	51207127 III Treatment Naive Fatients With Nev	3	30,00,2013	Closed - In Follow	raiget wet with
11/LO/0743	PARACHUTE III	4	01/06/2013		Target Not Met
, -, -			, , , , , ,	- 1	Still open to
12/LO/1090	NCRN: 416 MetMAb - YO28322	4	01/06/2015	Open	Recruitment
	NCRN469 COMET 1: Cabozantinib vs Prednisone in mCRPC after prior			Closed - In Follow	
12/LO/1156	therapy	5	16/09/2013	Up	Target Not Met
					Still open to
12/NW/0367	MCRN177 (BEL114055)	1	31/12/2014	Open	Recruitment
	V72P12E2 - A new vaccine against meningitis groupB: A second follow-			Closed - Follow	
12/SC/0384	on	52	31/08/2013	Up Complete	Target Met
					Still open to
12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4	30/06/2014	Open	Recruitment
12/SC/0502	Pfizer B1181003 Clinical Study of RN6G (PF-04382923)	3	30/06/2014	Withdrawn	Withdrawn
	NCRN398 IMAGE: Observational Study in Patients with Unresectable				Still open to
12/WA/0058	or Metastatic Melanoma	10	31/07/2014	Open	Recruitment
	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with				Still open to
13/EM/0012	malignant melanoma	1	30/06/2016		Recruitment
	CCRN 2010 - Baxter 261201: PEGylated Recombinant Factor VIII in			Closed - In Follow	
13/EM/0084	Severe Hemophilia A	2	31/10/2013	Up	Target Met
					Still open to
13/LO/0150	RESORCE: The regorafenib in patients with hepatocellular carcinoma	2	01/02/2015		Recruitment
	OCTAVE, Ranibizumab in neovascular age-related macular			Closed - In Follow	
13/LO/0520	degeneration(CRFB002A2405)	4	16/04/2016	Up	Target Met
				_	Still open to
13/YH/0021	MCI-196-E15 Extension Study Evaluating Colestilan	2	31/12/2014	Open	Recruitment
				_	Still open to
13/YH/022	MCI-196-E16	2	31/07/2014	•	Recruitment
13/SW/0072	FTY720D2205 (CCRN 2149)	3	31/12/2013		Withdrawn
13/SC/0171	VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis	3	31/12/2013	witnarawn	Withdrawn
12/11/1/1064	7507		21/12/2014	0222	Still open to
12/WA/1064	ZEST Extension study of GS-7977 in patients with HCV infection (GS-US-334-	4	31/12/2014	Closed - In Follow	Recruitment
12/EE/0400	0109)	5	27/01/2014		Target Not Met
12/11/0400	0105)	,	27/01/2014	Ор	Still open to
13/SC/0213	ACT IV Study - Protocol CDX110-04	6	01/06/2014	Onen	Recruitment
13/30/0213	CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven	Ü	01/00/2011	Орен	Still open to
13/EM/0254	Macular Oedema (CRFB002G2302)	2	31/08/2014	Open	Recruitment
,,		<u> </u>	0 = , 0 0 , = 0 = 1	- F	Still open to
13/NW/0464	CCRN 2274 (Liver failure)	4	02/04/2014	Open	Recruitment
			, , ,	Closed - In Follow	
12/LO/1876	COBRIM - GO28141	5	31/12/2013	Up	Target Not Met
					Still open to
12/NW/0641	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	8	31/12/2014	Open	Recruitment
					Still open to
13/EE/0263	MASTER II Trial	20	31/12/2014	Open	Recruitment
				Closed - In Follow	
13/NW/0320	MCRN235 (WA28117)	2	30/04/2016	Up	Target Met
					Still open to
13/WA/0101	CCRN 2088 (Pneumonia)	6	30/04/2016	Open	Recruitment
					Still open to
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	2	28/11/2014	Open	Recruitment
	ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461 in				Still open to
13/NE/0294	wAMD	5	30/04/2014	Open	Recruitment
	MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection				Still open to
12/EE/0257	(MK5172-047)	1	02/06/2014	Open	Recruitment
	ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial				
	of SGI-110 and Carboplatin in Subjects with Platinum-Resistant				Still open to
13/LO/0615	Recurrent Ovarian Cancer	3	31/07/2014	Open	Recruitment
	22224		04/		Still open to
GTAC185	PROSTVAC	5	31/08/2014	Open	Recruitment
42 / 0 / 22 : =	MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of children		24/10/55		Still open to
13/LO/0945	with phenylketOnuria)	2	31/10/2014	Open	Recruitment
Ī		1			Still open to
13/YH/0136	CCRN 2173 (Al Liver Decompensation)	2	30/03/2015	•	Recruitment

## **Commercial Recruitment to Target**

Research Ethics		Recruit			
Committee		ment	Recruitment		Performance Against
Reference	Study Title	Target	End Date	Study Status	Target
					Still open to
13/ES/0005	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC)	2	30/06/2015	Open	Recruitment
					Still open to
13/LO/1283	MO 28037 - TAMIGA	6	30/10/2015	Open	Recruitment
				Closed - In Follow	
13/NW/0321	MCRN234 (WA28118)	2	30/04/2016	Up	Target Met
	NCRN325 HOPE: E7080 +/- Everolimus in mRCC following one prior			Closed - In Follow	
11/LO/0619	VEGF-targeted treatment	4	31/10/2013	Up	Target Not Met
				Closed - In Follow	
13/SC/0452	VX12-809-105 CF Rollover study	1	15/03/2014	Up	Target Met
	·				Still open to
12/EE/0071	CCRN 923 (Ascites)	6	30/06/2014	Open	Recruitment
					Still open to
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	15	30/06/2014	Open	Recruitment
	M12-813: Elagolix in Premenopausal Women with Heavy Menstrual				Still open to
13/EE/0377	Bleeding Associated with Uterine Fibroids	4	31/07/2014	Open	Recruitment
					Still open to
14/EM/0001	TREND	5	05/09/2014	Open	Recruitment
					Still open to
13/SW/0186	EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment	4	24/09/2014	Open	Recruitment
	NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation postive				Still open to
13/LO/0720	melanoma patients	2	30/09/2014	Open	Recruitment
	·				Still open to
13/WA/0269	CCRN 771 (Endometriosis-related pain)	4	30/10/2014	Open	Recruitment
					Still open to
13/WS/0304	EVARREST™ (The Fibrin Pad CV Phase III Study)	10	14/11/2014	Open	Recruitment
					Still open to
13/YH/0020	MCRN222 (MCI-196-E14)	1	28/02/2015	Open	Recruitment
					Still open to
14/WM/0013	Developing a new drug to treat infants hospitalised with RSV infection	8	30/04/2015	Open	Recruitment
					Still open to
14/NW/0001	Continuation Study of Prophylactic BAX 855 in PTP with Haemophilia A	2	31/05/2016	Open	Recruitment